Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Fibrosis

Our scientists’ deep understanding of cellular models and expertise in the pathology of fibrosis has led to the development of a robust and predictive in vitro model organ-specific fibrosis using confocal microscopy in either a 2D or 3D cell culture format. Our models are used to support compound profiling across a diverse range of client projects for which organ-specific fibrosis presents as a disease pathology.

Sygnature’s fibrosis model can be used to profile your potential anti-fibrotic agents in a high-throughput manner by following biomarker expression. Our model enables the study of fibrosis-related parameters in response to drug treatment such as stellate cell activation, extracellular matrix deposition, changes in pro-fibrotic mRNA expression and specific fibrotic signalling events (e.g. TGF-β/Smad3, and TGF-β receptor dimerization).

Our models can be used to investigate compound Mechanism of Action and to support integrated Hit Identification and Lead Optimisation drug discovery cascades, with our scientific team providing intellectual input into project screening strategies and progression pathways and meaningful data interpretation.

Co-culture models of organ fibrosis: Human lung fibroblast WI38 and human lung epithelial cells A549 can be co-cultured to provide a more physiologically relevant model of lung fibrosis.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.